Amgen Lawsuit Battles Colorado Board’s “Unaffordable” Drug Classification

Pharmaceutical company Amgen has initiated a lawsuit against the Colorado Prescription Drug Affordability Review Board. This legal action was prompted when Amgen’s arthritis drug was adjudged as being “unaffordable” by the board. Amgen counters this classification with a claim that the board employs an unconstitutionally “unguided discretion” to establish unsystematic cost boundaries on drugs that are secured by patents.

In this case, the contention revolves around determining what classifies as unaffordable in the healthcare market. The pharmaceutical company’s assertion that the board’s actions infringe on constitutional rights adds a fresh legal perspective to this ongoing tension between healthcare cost and accessibility.

Only time will tell how this lawsuit progresses and what potential impact it could have on the way drug pricing is regulated in Colorado and perhaps, across the United States. More detailed information about this ongoing legal dispute was reported by Law360.